New podcast coming next week!

"We can flex the support that we provide. We're not just a facility where (ATMP start-ups) can manufacture. We want them to come in, build that capability, leave, build their own facility, engage with the CDMO network, do something in the UK, and leave a space where someone can come in behind them".

We are excited to announce the launch of our next podcast, and the last in our current series, featuring?Kasia Averall, Head of Cluster Development at?Cell and Gene Therapy Catapult! The full podcast will be available next week, and a snippet from the episode can be viewed here.

Many people are familiar with the concept of Cell & Gene Therapy Catapult, and other Catapult organisations which support the growth and innovation of businesses in the UK. But how has the CGT Catapult model evolved over the last few years, and how does it look in 2023?

It is fascinating listening to?Kasia, who was instrumental in developing a QMS that worked in partnership with each of CGTC's collaborators, and for the last 2 years has been in a more outwardly-facing role, optimising relationships and logistics between CGTC and their partners.

If you are involved in QMS development within a biologics / ATMP setting, we hope you will find this discussion fascinating!

The full podcast will be going live on our?Next Phase Recruitment?page next week, exploring the challenges of building a QMS that is fit for purpose when multiple parties are involved, and going on to talk more broadly about what Cell & Gene Catapult do, and how their role has evolved over the last few years in facilitating the research, development and production of Advanced Therapies in the UK.

Please follow our?Next Phase Recruitment?page for further updates!